Friday, 03 Apr 2020

You are here

Bimekizumab Effective in Active Psoriatic Arthritis

Interleukin 17 IIL-17) is important in the pathogenesis of psoriatic disease, with most current approaches targeting IL-17A. Now there is a novel approach showing that dual neutralisation of IL-17A and IL-17F in psoriatic arthritis arthritis patients results in clinically significant improvement. 

Bimekizumab (BMK) is a monoclonal antibody that selectively neutralises IL17A and IL17 and has been studied in the BE ACTIVE trial; a phase 2b randomised, double-blind, placebo-controlled, worldwide study done in patients with active psoriatic arthritis.

Adults (n=206) with active psoriatic arthritis randomized to receive placebo, or 4 different doses of bimekizumab (16 mg, 160 mg, 160 mg after a 320 mg loading dose), or 320 mg bimekizumab, given subcutaneously every 4 weeks for 12 weeks. The primary endpoint was the ACR50 response rate at week 12, although patients were followed till week 48. 

At 12 weeks, the odds of achieving an ACR50 response (compared with placebo) was: 

  • BMK 16 mg - odds ratio [OR] 4·2 [95% CI 1·1–15·2]; p=0·032)
  • BMK 160 mg - OR 8·1 [2·3–28·7]; p=0·0012
  • BMK 160 mg + 320 mg Loading - OR 9·7 [2·7–34·3]; p=0·0004

ACR50 response rates were:

  • Placebo 7%
  • 16 mg 27%
  • 160 mg 41%
  • 160 + 320mg Loading 47%
  • 320 mg 24% (not significant p=0.51)

By week 24, 37–60% of patients who remained on the same dose of bimekizumab from baseline had minimal disease activity, and these were maintained out to week 48.

Skin responses in patients with psoriasis affecting at least 3% of their BSA, showed bimekizumab groups were significantly more likely to achieve PASI75 (p≤0·0048) and that those in the 160 mg, 160 mg (loading dose), and 320 mg bimekizumab groups were significantly more likely to achieve PASI90 (p≤0·0020).

Adverse events were similar between groups (57% placebo vs. 41% BMK) with mild or moderate.  However eight of nince serious adverse events were with bimekizumab, but there were no deaths or cases of inflammatory bowel disease reported.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

No Cancer Increase in Psoriatic Arthritis or with Biologics in Psoriasis

JAMA Dermatology reports that psoriasis is associated with a slightly increased risk of cancer, particularly keratinocyte cancer and lymphomas.

A systematic review and meta-analysis of 112 studies including more than 2 million patients, also shows no increase in when psoriasis is treated with biologic agents, nor was psoriatic arthritis associated with an increased risk of cancer.   

Upadacitinib Effective in Phase 3 Psoriatic Arthritis Study

Abbvie has announced top line results of their SELECT-PSA trial of upadacitinib (UPA), wherein both the 15 and 30 mg doses met the primary endpoint of ACR20 response at week 12 and demonstrated radiographic inhibition at week 24.

Which Biologics are Best in Psoriasis

A metanalysis of phase II, III and IV trials in moderate to severe plaque psoriasis suggests comparative efficacy biologic treatments, but that that brodalumab, guselkumab, ixekizumab, and risankizumab-rzaa were shown to have the past skin (PASI) response rates.

Taltz Shines in Non-Radiographic Axial Spondyloarthritis

Ixekizumab (IXE), an interleukin-17A (IL-17A) inhibitor, was recently approved for use in ankylosing spondylitis (also known as radiographic axial spondyloarthritis- axSpA). Lancet has published the results of the COAST-X study showing that ixekizumab was effective in patients with non-radiographic axial spondyloarthritis.

Best of 2019 - SEAM-PsA Study - Does Monotherapy MTX Win Despite Losing to Etanercept in Psoriatic Arthritis?

The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.